Search

  • Select Article Type
  • Abstract Supplements
  • Blood Group Review
  • Call to Arms
  • Hypothesis
  • In Memoriam
  • Interview
  • Introduction
  • Letter to the Editor
  • Short Report
  • abstract
  • Abstracts
  • Article
  • book-review
  • case-report
  • case-study
  • Clinical Practice
  • Commentary
  • Conference Presentation
  • conference-report
  • congress-report
  • Correction
  • critical-appraisal
  • Editorial
  • Editorial Comment
  • Erratum
  • Events
  • Letter
  • Letter to Editor
  • mini-review
  • minireview
  • News
  • non-scientific
  • Obituary
  • original-paper
  • original-report
  • Original Research
  • Pictorial Review
  • Position Paper
  • Practice Report
  • Preface
  • Preliminary report
  • Product Review
  • rapid-communication
  • Report
  • research-article
  • Research Communicate
  • research-paper
  • Research Report
  • Review
  • review -article
  • review-article
  • review-paper
  • Review Paper
  • Sampling Methods
  • Scientific Commentary
  • short-communication
  • short-report
  • Student Essay
  • Varia
  • Welome
  • Select Journal
  • Immunohematology

 

Article | 15-February-2021

Serologic problems associated with administration of intravenous immune globulin (IVIg)

Introduction Preparations of intravenous immune globulin (intravenous gamma globulin; IVIg) are produced from large pools of donor plasma. One lot of IVIg is produced by pooling the plasma of up to 60,000 donors.1,2 IVIg was first produced in the 1970s after the development of the cold alcohol fractionation process (Cohn fractionation) of antibodies from pooled plasma; the final product contains mostly IgG.3–6 The original use for IVIg was as antibody replacement for patients, mostly children

D.R. Branch

Immunohematology, Volume 35 , ISSUE 1, 13–15

Case report | 16-May-2020

Case report: exacerbation of hemolytic anemia requiring multiple incompatible RBC transfusions

hospital admission for further management of her hemolytic anemia and angina. She subsequently required multiple incompatbile RBC transfusions despite increased prednisone therapy and did not improve until after coronary artery stent placement and high dose IVIG therapy. This case demonstrates the usefulness of early patient phenotyping in a case of accelerating hemolytic anemia to aid in donor RBC selection, the value of communicating with clinicians and the patient regarding the use of least

Annika M. Svensson, Sharon Bushor, Mark K. Fung

Immunohematology, Volume 20 , ISSUE 3, 177–183

Article | 16-February-2021

A case of platelet transfusion refractoriness due to anti-CD36 with a successful treatment outcome

, given over this 14-day period, ranged from 0 to 0.82 (Fig. 1). All CCIs reported in Table 1 were calculated from PLT counts within 1 hour after the PLT transfusion. Fig. 1 Types of platelets (PLTs), corrected count increment (CCI), HLA and CD36 antibody levels, and medications for immune suppression over the course. HLA class I panel reactive antibody (PRA), anti-CD36 titer decrease, and CCI increase after the third intravenous immunoglobulin (IVIG) infusion are shown. Table 1. CCI achieved with

S.S. Khatri, B.R Curtis, C. Yamada

Immunohematology, Volume 35 , ISSUE 4, 139–144

Case report | 16-March-2020

Autoantibody formation after alloimmunization inducing bystander immune hemolysis

was present in the eluate, and the antibody investigation revealed the presence of anti-Jkb in addition to the previously identified alloanti-c. Her genotype was determined, and, based on the findings, two additional units were selected, found to be compatible, and transfused without incident. Transfusions were discontinued, and she was treated with IVIG and corticosteroids. Her Hb increased to 9.7 g/dL, and the patient made an uneventful recovery. It was concluded that transfusion of incompatible

Mariza Mota, C. Bley, M.G. Aravechia, N. Hamerschlak, A. Sakashita, J.M. Kutner, L. Castilho

Immunohematology, Volume 25 , ISSUE 1, 9–12

Article | 14-October-2020

Neonatal alloimmune thrombocytopenia due to anti-HPA-2b (anti-Koa)

Most severe cases of neonatal alloimmune thrombocytopenia (NAIT) are due to anti-HPA-1a (anti-PlA1) antibodies. We report a case of NAIT due to anti-HPA-2b that resulted in in utero intracranial hemorrhage.A 33-year-old G2P1A0 Caucasian woman had a routine ultrasound at 34 weeks. The fetus appeared to have a left hemispheric hematoma. IVIG, 1g/kg, was started immediately and administered weekly until delivery. One day after receiving the first dose of IVIG, fetal platelet count was 18 ×

Mindy Goldman, Élise Trudel, Samir Khalife, Gwendoline M. Spurll

Immunohematology, Volume 19 , ISSUE 2, 43–46

Article | 17-November-2020

Acute hemolysis due to passively transfused high-titer anti-B causing spontaneous in vitro agglutination

Intravascular hemolysis due to passive transfer of anti-A or anti-B has been a frequently reported transfusion complication. In most reported cases, passive anti-A has been implicated. However, cases of hemolysis due to anti-B have also been reported following administration of intravenous immunoglobulin (IVIG) and during platelet transfusions. In our case, a 6-day-old infant with E. coli sepsis underwent double-volume exchange transfusion for hyperbilirubinemia. Modified whole blood used

Gregg Boothe, Mark E. Brecher, Mamie B. Root, Judy Robinson, Nancy R. Haley

Immunohematology, Volume 11 , ISSUE 2, 43–45

Case report | 21-March-2020

Hyperhemolytic transfusion reaction attributable to anti-Fy3 in a patient with sickle cell disease

Hb decreased to 2.4 g/dL. The LDH level was 1687 U/L, and her reticulocyte count was 2.6%. A delayed hemolytic transfusion reaction with hyperhemolysis secondary to anti-Fy3 was suspected and was successfully treated with IVIG and high-dose prednisone. To the best of our knowledge, this is the first published case of hyperhemolysis in sickle cell disease attributable to anti-Fy3.

Meredith A. Reyes, Orieji C. Illoh

Immunohematology, Volume 24 , ISSUE 2, 45–51

Case report | 26-October-2019

Anti-Jk3 in a Filipino man

Shaina McCaskill, Scott Wise, Sheila Tinsley

Immunohematology, Volume 31 , ISSUE 3, 119–122

No Record Found..
Page Actions